"Black Box" Will Not Deter Off-Label Zyprexa Use In Dementia Patients, Lilly Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company points to the lack of indicated alternatives for treating dementia-related psychosis as one reason why psychiatrists will continue to prescribe atypical antipsychotics despite a new "black box" warning on mortality in that patient population. First quarter U.S. Zyprexa sales fell 17% compared to the same period in 2004.